ARVINAS, INC. — Director's Dealing 2018

Sep 28, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARVINAS HOLDING COMPANY, LLC (ARVN)
CIK: 0001655759
Period of Report: 2018-09-26

Reporting Person: Houston John G (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-26	Stock Option (right to buy)	$16.00	A	106900	Acquired	2028-09-25	Common Stock (106900)	Direct
2018-09-26	Stock Option (right to buy)	$16.00	A	13360	Acquired	2028-09-25	Common Stock (13360)	Direct
2018-09-26	Stock Option (right to buy)	$16.00	A	13360	Acquired	2028-09-25	Common Stock (13360)	Direct
2018-09-26	Stock Option (right to buy)	$16.00	A	200440	Acquired	2028-09-25	Common Stock (200440)	Direct
2018-09-26	Stock Option (right to buy)	$16.00	A	132880	Acquired	2028-09-25	Common Stock (132880)	Direct

Footnotes

F1: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.

F2: This option award was granted on September 26, 2018 and will vest upon achievement of a regulatory milestone for the Issuer's androgen receptor program.

F3: This option award was granted on September 26, 2018 and will vest upon achievement of a regulatory milestone for the Issuer's estrogen receptor program.

F4: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of September 15, 2018, with the remainder of the shares vesting in equal monthly installments following September 15, 2018 through September 15, 2021.

F5: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.